Human Imaging Shared Facility

成像集团 人类成像共享因子（HISF） 摘要 人类成像共享设施（HISF）增强了UAB中包含的成像相关研究活动- CCC的协作组组合和其他临床试验，通过提供标准化的方法， 审查每个UAB-CCC方案并协调非常规成像服务。方案审查是 由两名研究成像协调员执行，他们为常规和非常规研究提供报价 符合机构和国家法规的成像服务。其他HISF服务包括图像 数据传输和协议特定成像技术，体模扫描/部位鉴定成像，物理学家， 放射科医师或放射技术人员的时间，以及图像数据表格的信息的获取。图像数据 传输符合所有UAB卫生系统信息安全（HSIS）要求，并定期进行审核 的UAB HSIS。用于缓解评估的常规成像研究的准确和及时分析 在癌症临床试验中，为UAB-CCC成员提供的大部分服务。具有专用 专科放射科医师解释协调的协助下，两个放射学研究 成像协调器和度量协调器，协议特定的度量由同一组 在每个治疗试验的整个过程中指定阅读者，以获得一致的纵向指标报告。 在裁定的情况下，HISF主任与PI和协调员合作解决报告问题。 HISF促进了新型反应评价方法（成像）的开发和整合 生物标志物）用于癌症临床前、转化和I-III期临床试验。通过科学合作 HISF可以促进更复杂的成像检查、图像分析和 其他成像核心（如临床前成像共享设施和综合 定量成像生物标志物分析和开发核心。这些非标准的高级图像 分析包括生理MRI（扩散加权成像、动态对比MRI、MR光谱）， 研究用PET CT、PET MRI和能谱（双能量）MDCT。标准指标和高级指标 成像方法将有助于UAB-CCC项目的研究人员。

IMAGING GROUP HUMAN IMAGING SHARED FACILITY (HISF) ABSTRACT The Human Imaging Shared Facility (HISF) enhances imaging-related research activities included in the UAB- CCC's collaborative group portfolio and other clinical trials through the provision of a standardized approach for reviews of each UAB-CCC protocol and coordination of non-routine imaging services. The protocol review is performed by two research imaging coordinators who provide quotes for routine and nonroutine research imaging services in compliance with institutional and national regulations. Other HISF services include image data transfers and protocol specific imaging techniques, phantom scan/site qualification imaging, physicist, radiologist, or radiology technologist time, and procurement of information for image data forms. Image data transfers meet all UAB Health System Information Security (HSIS) requirements and are audited periodically by the UAB HSIS. Accurate and timely analysis of conventional imaging studies used for response assessment in cancer clinical trials makes up the bulk of services provided to members of the UAB-CCC. With dedicated subspecialty faculty radiologist interpretations coordinated by the assistance of the two radiology research imaging coordinators and a metrics coordinator, protocol-specific metrics are generated by the same set of designated readers throughout the course of each therapeutic trial for consistent longitudinal metrics reporting. In cases of adjudication, the HISF Director works with the PIs and coordinators to resolve reporting issues. The HISF promotes the development and incorporation of novel response evaluation methods (imaging biomarkers) for cancer preclinical, translational, and Phase I-III clinical trials. Through scientific collaboration the HISF can facilitate the translation of more sophisticated imaging examinations, image analytics, and metrics utilized by the other imaging cores such as the Preclinical Imaging Shared Facility and Comprehensive Core for Quantitative Imaging Biomarker Analysis and Development. These non-standard advanced image analyses include physiologic MRI (diffusion weighted imaging, dynamic contrast MRI, MR Spectroscopy), investigational PET CT, PET MRI, and Spectral (dual energy) MDCT. Both standard metrics and advanced imaging methods will aid investigators in UAB-CCC programs.